Oncocross Co., Ltd.

Oncocross Co., Ltd. is a South Korean company that develops drugs for cancers, rare diseases, and intractable diseases. Its pipeline includes OC101 for liver cirrhosis, OC101+OC111 for non-alcoholic steatohepatitis, OC201+OC202e for inhibition of cancer metastasis, OC211 (a Pan-KRAS inhibitor), OC221 (an immuno-oncology combination), OC514 for amyotrophic lateral sclerosis and Duchenne muscular dystrophy, and OC701 for atopic dermatitis. The company is also developing OJP3101 for metabolic disease and cardiovascular disease, ODP9401 for metabolic disease, and ODP2201, ODP2301, and ODP2401 for oncology-related diseases. Founded in 2015 and based in Seoul, South Korea, it has collaboration agreements with various pharmaceutical companies, research institutes, and biotech firms.